We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
36 hedge funds and large institutions have $3M invested in Crescent Biopharma in 2024 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 4 increasing their positions, 12 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
3% more funds holding
Funds holding: 35 → 36 (+1)
0.12% less ownership
Funds ownership: 0.4% → 0.28% (-0.12%)
58% less capital invested
Capital invested by funds: $7.2M → $3M (-$4.19M)
67% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 12
Holders
36
Holders Change
+1
Holders Change %
+2.86%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
4
Reduced
12
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Two Sigma Advisers
New York
|
+$29.4K |
| 2 |
HWA
HCR Wealth Advisors
Los Angeles,
California
|
+$21K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$17.6K |
| 4 |
Two Sigma Investments
New York
|
+$9.36K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.13K |
Top Sellers
| 1 |
AG
Artal Group
Luxembourg
|
-$2.42M |
| 2 |
Goldman Sachs
New York
|
-$227K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$37.2K |
| 4 |
Millennium Management
New York
|
-$35.1K |
| 5 |
SIG
Sargent Investment Group
Bethesda,
Maryland
|
-$28.2K |
